甲亢性骨质疏松的研究进展  

Research Progress of Osteoporosis in Patients with Hyperthyroidism

作　　者：胡卓清 杜敏群 崔燎 

机构地区：[1]广东医科大学附属医院内分泌科,广东省湛江市524001 [2]广东医科大学药理学教研室,广东省湛江市524001 [3]广东省天然药物研究与开发重点实验室,广东省湛江市524001

出　　处：《中国全科医学》2017年第25期3187-3190,3194,共5页Chinese General Practice

基　　金：国家自然科学基金资助项目(81273518)

摘　　要：甲状腺功能亢进症(甲亢)引起的继发性骨质疏松是继糖尿病性骨质疏松之后又一研究热点。本文旨在对甲亢性骨质疏松的研究进展进行综述,结果表明甲亢是继发性骨质疏松的常见病因,促甲状腺激素(TSH)的降低可能独立于甲状腺激素(TH)参与其中。多数临床研究显示甲亢可致净骨量丢失,骨密度(BMD)下降致骨质疏松,甚至可增加未来骨折的风险。积极的抗甲亢及补钙辅助治疗是目前较确切有效对抗甲亢性骨质疏松的策略。甲亢性骨质疏松的发病机制及临床研究方兴未艾,未来需要更多更高质量的研究予以探讨。Hyperthyroidism is a common cause of secondary osteoporosis. The decrease of thyroid stimulating hormone may be independent of thyroid hormone and takes part in the process of secondary osteoporosis separately. Most clinical studies have shown that hyperthyroidism can cause the net bone loss, and the decreased bone mineral density induces the osteoporosis, and even furthermore increases the risk of fractures. Positive anti - hyperthyroidism treatment assisted with adjuvant calcium therapy is the most effective strategy against osteoporosis in patients with hyperthyroidism. Clinical research on the pathogenesis of osteoporosis in patients with hyperthyroidism has just risen and more high quality researches will be need in the future.

关 键 词：甲状腺功能亢进症 骨质疏松 骨密度 骨折 综述 

分 类 号：R581.1[医药卫生—内分泌] R681.4[医药卫生—内科学]